Previous 10 | Next 10 |
Pulmatrix (PULM) inks agreements with institutional investors for the purchase and sale of 20M common shares at $2.00/share, in a registered direct offering.Expected gross proceeds are $40M. Net proceeds will be used for working capital and general corporate purposes.Closing date is February ...
Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire LEXINGTON, Mass. , Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative i...
Marine Petroleum Trust (MARPS) -43%.Barnwell Industries (BRN) -39%.Tengasco (TGC) -32%.PEDEVCO (PED) -34%.New Concept Energy (GBR) -30% pared yesterday's gains following latest Reddit craze.Ucommune International (UK) -28% after pricing share and warrant offering.Hous...
What Are Penny Stocks? Penny stocks are shares of companies trading under $5. So when it comes to making a list of these cheap stocks, your choices are pretty open. However, in today’s trading world, access to certain penny stocks might also depend on the broker you...
Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates Focused pipeline with multiple potential clinical and regulatory milestones in 2021 Pulmatrix to receive escalating royalties from partner Sensory Cloud upon sales of FEND, an OTC nasal hygiene produ...
Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud Series of Scientific Publications Demonstrate up to 99% Reduction of Airborne Respiratory Droplets Including Those not Captured ...
Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles FEND Administration Lowered Exhaled Particles in Subjects Including Healthy Subjects and a COVID-19 Patient Partne...
Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore PR Newswire LEXINGTON, Mass., Sept. 29, 2020 LEXINGTON, Mass. , Sept. 29, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company devel...
Pulmatrix Reports Progress on Product Pipeline PR Newswire LEXINGTON, Mass., Sept. 22, 2020 LEXINGTON, Mass. , Sept. 22, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapie...
Pulmatrix (NASDAQ: PULM ) : Q2 GAAP EPS of -$0.05 beats by $0.33 . More news on: Pulmatrix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...